1. Home
  2. MNTS vs DRMA Comparison

MNTS vs DRMA Comparison

Compare MNTS & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Momentus Inc.

MNTS

Momentus Inc.

HOLD

Current Price

$4.45

Market Cap

6.9M

Sector

Industrials

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$1.15

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNTS
DRMA
Founded
2017
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9M
5.6M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
MNTS
DRMA
Price
$4.45
$1.15
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
539.4K
48.2K
Earning Date
05-21-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,110,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$650.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.44
$0.95
52 Week High
$22.20
$5.87

Technical Indicators

Market Signals
Indicator
MNTS
DRMA
Relative Strength Index (RSI) 52.55 40.22
Support Level $3.97 $1.14
Resistance Level $5.21 $1.40
Average True Range (ATR) 0.21 0.08
MACD 0.08 -0.02
Stochastic Oscillator 89.80 29.13

Price Performance

Historical Comparison
MNTS
DRMA

About MNTS Momentus Inc.

Momentus Inc offers in-space infrastructure services by building transfer and service vehicles that carry satellites and hosted payloads between orbits in space. It is a provider of three critical functions, in the new space economy: Space Transportation, Satellite as a Service, and In-Orbit Servicing.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Share on Social Networks: